Revista: | Memorias do Instituto Oswaldo Cruz |
Base de datos: | PERIÓDICA |
Número de sistema: | 000391447 |
ISSN: | 0074-0276 |
Autors: | Fernández, Marisa Liliana1 Marson, Maria Elena2 Ramírez, Juan Carlos3 Mastrantonio, Guido2 Schijman, Alejandro Gabriel3 Altcheh, Jaime4 Riarte, Adelina Rosa1 Bournissen, Facundo García4 |
Institucions: | 1Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben", Buenos Aires. Argentina 2Universidad Nacional de La Plata, Facultad de Ciencias Exactas, La Plata, Buenos Aires. Argentina 3Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Laboratorio de Biología Molecular de la Enfermedad de Chagas, Buenos Aires. Argentina 4Hospital de Niños Ricardo Gutiérrez, Servicio de Parasitología-Chagas, Buenos Aires. Argentina |
Any: | 2016 |
Període: | Mar |
Volum: | 111 |
Número: | 3 |
Paginació: | 218-221 |
País: | Brasil |
Idioma: | Inglés |
Tipo de documento: | Artículo |
Enfoque: | Experimental, aplicado |
Resumen en inglés | Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective |
Disciplines | Medicina |
Paraules clau: | Farmacología, Enfermedad de Chagas, Benznidazol, Adultos, Farmacocinética, Farmacodinamia |
Keyword: | Medicine, Pharmacology, Chagas disease, Benznidazole, Adults, Pharmacokinetics, Pharmacodynamics |
Text complet: | Texto completo (Ver HTML) |